{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:19:35Z","timestamp":1768781975782,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s13555-025-01367-5","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T13:05:16Z","timestamp":1741871116000},"page":"889-901","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Incidence of Conjunctivitis and Keratitis Among Individuals with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab in the United States: a Cohort Study in Routine Care Based on Healthcare Claims"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8941-4116","authenticated-orcid":false,"given":"Jessica M.","family":"Franklin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea F.","family":"Marcus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ihtisham","family":"Sultan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Howell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah-Jo","family":"Sinnott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeannette","family":"Green","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Ezzy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Gately","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel E.","family":"Sobel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence T.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"key":"1367_CR1","first-page":"1","volume":"9","author":"T Alexander","year":"2017","unstructured":"Alexander T, Maxim E, Cardwell LA, et al. Prescriptions for atopic dermatitis: oral corticosteroids remain commonplace. J Dermatolog Treat. 2017;9:1\u201310.","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"1367_CR2","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jid.2018.08.028","volume":"139","author":"ZCC Fuxench","year":"2019","unstructured":"Fuxench ZCC, Block JK, Boguniewicz M, et al. Atopic dermatitis in america study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Invest Dermatol. 2019;139(3):583\u201390.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"1367_CR3","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1111\/ijd.14763","volume":"59","author":"G Birdi","year":"2020","unstructured":"Birdi G, Cooke R, Knibb RC. Impact of atopic dermatitis on quality of life in adults: a systematic review and meta-analysis. Int J Dermatol. 2020;59(4):e75\u201391. https:\/\/doi.org\/10.1111\/ijd.14763.","journal-title":"Int J Dermatol"},{"issue":"4","key":"1367_CR4","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1159\/000507246","volume":"236","author":"A Chiricozzi","year":"2020","unstructured":"Chiricozzi A, Esposito M, Gisondi P, Valenti M, Gori N, Giovanardi G, Bellinato F, De Simone C, Costanzo A, Fargnoli MC, Peris K. Disease severity is associated with alexithymia in patients with atopic dermatitis. Dermatology. 2020;236(4):329\u201335. https:\/\/doi.org\/10.1159\/000507246.","journal-title":"Dermatology"},{"issue":"6","key":"1367_CR5","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.3390\/jcm13061602","volume":"13","author":"A Courtney","year":"2024","unstructured":"Courtney A, Su JC. The psychology of atopic dermatitis. J Clin Med. 2024;13(6):1602. https:\/\/doi.org\/10.3390\/jcm13061602.","journal-title":"J Clin Med"},{"issue":"9","key":"1367_CR6","doi-asserted-by":"publisher","first-page":"5020","DOI":"10.3390\/ijms25095020","volume":"25","author":"C Alessandrello","year":"2024","unstructured":"Alessandrello C, Sanfilippo S, Minciullo PL, Gangemi S. An overview on atopic dermatitis, oxidative stress, and psychological stress: possible role of nutraceuticals as an additional therapeutic strategy. Int J Mol Sci. 2024;25(9):5020. https:\/\/doi.org\/10.3390\/ijms25095020.","journal-title":"Int J Mol Sci"},{"key":"1367_CR7","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","volume":"368","author":"S Wenzel","year":"2013","unstructured":"Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368:2455\u201366.","journal-title":"N Engl J Med"},{"key":"1367_CR8","unstructured":"Dupixent (dupilumab). Full Prescribing Information. Regeneron. Tarrytown, NY. 2022."},{"issue":"2","key":"1367_CR9","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.jaad.2020.11.037","volume":"85","author":"NH Ravn","year":"2021","unstructured":"Ravn NH, Ahmadzay ZF, Christensen TA, et al. Bidirectional association between atopic dermatitis, conjunctivitis and other ocular surface diseases: a systemic review and meta-analysis. J Am Acad Dermatol. 2021;85(2):453\u201361. https:\/\/doi.org\/10.1016\/j.jaad.2020.11.037.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1367_CR10","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jaad.2017.03.003","volume":"77","author":"JP Thyssen","year":"2017","unstructured":"Thyssen JP, Toft PB, Halling-Overgaard A-S, Gislason GH, Skov L, Egeberg A. Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis. J Am Acad Dermatol. 2017;77(2):280\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2017.03.003.","journal-title":"J Am Acad Dermatol"},{"key":"1367_CR11","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1023\/A:1017939725776","volume":"21","author":"S Sharma","year":"2001","unstructured":"Sharma S. Keratitis. Biosci Rep. 2001;21:419\u201344. https:\/\/doi.org\/10.1023\/A:1017939725776.","journal-title":"Biosci Rep"},{"issue":"3","key":"1367_CR12","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","volume":"181","author":"B Akinlade","year":"2019","unstructured":"Akinlade B, Guttman-Yassky E, de Bruin-Weller M, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019;181(3):459\u201373.","journal-title":"Br J Dermatol"},{"key":"1367_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad498.060","author":"M Zirwas","year":"2024","unstructured":"Zirwas M, Chovatiya R, Gold LS, Shumel B, Praestgaard A, Chen Z, Gonzalez T, Gherardi G, Lawless E. 564-conjunctivitis adverse events in dupilumab clinical trials. Br J Dermatol. 2024. https:\/\/doi.org\/10.1093\/bjd\/ljad498.060.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1367_CR14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2303951","volume":"389","author":"SP Bhatt","year":"2023","unstructured":"Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Cole J, Bafadhel M, Christenson SA, Papi A, Singh D, Laws E, Mannent LP, Patel N, Staudinger HW, Yancopoulos GD, Mortensen ER, Akinlade B, Maloney J, Lu X, Bauer D, Bansal A, Robinson LB, Abdulai RM, BOREAS Investigators. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. N Engl J Med. 2023;389(3):205\u201314. https:\/\/doi.org\/10.1056\/NEJMoa2303951.","journal-title":"N Engl J Med"},{"issue":"3","key":"1367_CR15","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40123-019-0191-9","volume":"8","author":"A Maudinet","year":"2019","unstructured":"Maudinet A, Law-Koune S, Duretz C, et al. Ocular surface disease induced by dupilumab in severe atopic dermatitis. Opthamol Ther. 2019;8(3):485\u201390.","journal-title":"Opthamol Ther"},{"issue":"3","key":"1367_CR16","doi-asserted-by":"crossref","first-page":"201","DOI":"10.18176\/jiaci.0481","volume":"30","author":"E Nettis","year":"2020","unstructured":"Nettis E, Bonzano L, Patella V, et al. Dupilumab-associated conjunctivitis in patients with atopic dermatitis: a multicenter real-life experience. J Investig Allergol Clin Immunol. 2020;30(3):201\u20134.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"6","key":"1367_CR17","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/ICO.0000000000002262","volume":"39","author":"P Liberman","year":"2020","unstructured":"Liberman P, Shifera AS, Berkenstock M. Dupilumab-associated conjunctivitis in patients with atopic dermatitis. Cornea. 2020;39(6):784\u20136.","journal-title":"Cornea"},{"key":"1367_CR18","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1111\/all.15717","volume":"78","author":"R Achten","year":"2023","unstructured":"Achten R, Thijs J, van der Wal M, et al. Dupilumab-associated ocular surface disease in atopic dermatitis patients: clinical characteristics, ophthalmic treatment response and conjunctival goblet cell analysis. Allergy. 2023;78:2266\u201376. https:\/\/doi.org\/10.1111\/all.15717.","journal-title":"Allergy"},{"issue":"2","key":"1367_CR19","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jaad.2020.09.084","volume":"84","author":"M Schneeweiss","year":"2021","unstructured":"Schneeweiss M, Kim SC, Wyss R, et al. Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: a propensity score-matched cohort study. J Am Acad Dermatol. 2021;84(2):300\u201311.","journal-title":"J Am Acad Dermatol"},{"issue":"6S1","key":"1367_CR20","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1097\/DER.0000000000000843","volume":"33","author":"M Schneeweiss","year":"2022","unstructured":"Schneeweiss M, Wyss R, Chin K, et al. Incidence of Bacterial and Nonbacterial Conjunctivitis in Patients with Atopic Dermatitis Treated With Dupilumab: A US Multidatabase Cohort Study. Dermatitis. 2022;33(6S1):S73\u201382.","journal-title":"Dermatitis"},{"key":"1367_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljac140.041","author":"A Chomistek","year":"2023","unstructured":"Chomistek A, Franklin JM, Sobel R, et al. 348 development and validation of a claims-based algorithm for moderate-to-severe atopic dermatitis using U.S. real-world data. Br J Dermatol. 2023. https:\/\/doi.org\/10.1093\/bjd\/ljac140.041.","journal-title":"Br J Dermatol"},{"key":"1367_CR22","volume-title":"Development and validation of claims-based algorithms for conjunctivitis and keratitis","author":"A Chomistek","year":"2023","unstructured":"Chomistek A, Franklin JM, Sobel R, et al. Development and validation of claims-based algorithms for conjunctivitis and keratitis. Halifax, Nova Scotia, Canada: ICPE; 2023."},{"key":"1367_CR23","unstructured":"Parsons LS. Reducing Bias in a Propensity Score Matched-pair Sample Using Greedy Matching Techniques. Paper 214\u201326 in Proceedings of the Twenty-Sixth Annual SAS Users Group International Conference. Long Beach, California: SAS Institute, Inc; 2001. http:\/\/www2.sas.com\/proceedings\/sugi26\/p214-26.pdf. Accessed 18 November 2020."},{"key":"1367_CR24","volume-title":"Epidemiology: An Introduction","author":"KJ Rothman","year":"2002","unstructured":"Rothman KJ. Epidemiology: An Introduction. New York, New York: Oxford University Press; 2002."},{"issue":"6","key":"1367_CR25","volume":"7","author":"Y-H Chen","year":"2017","unstructured":"Chen Y-H, Lin C-L, Bau D-T, et al. Risk of allergic conjunctivitis in patients with type 1 diabetes mellitus: a population-based retrospective cohort study. BMJ Open. 2017;7(6): e015795.","journal-title":"BMJ Open"},{"key":"1367_CR26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12886-017-0645-6","volume":"18","author":"L Zhu","year":"2018","unstructured":"Zhu L, Liu B, Zhong J. Post-traumatic right carotid-cavernous fistula resulting in symptoms in the contralateral eye: a case report and literature review. BMC Ophthalmol. 2018;18:1\u20137.","journal-title":"BMC Ophthalmol"},{"issue":"16","key":"1367_CR27","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jama.2013.280318","volume":"310","author":"AA Azari","year":"2013","unstructured":"Azari AA, Barney NP. Conjunctivitis: a systematic review of diagnosis and treatment. JAMA. 2013;310(16):1721\u20139.","journal-title":"JAMA"},{"issue":"10","key":"1367_CR28","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1001\/jamadermatol.2018.2690","volume":"154","author":"AD Treister","year":"2018","unstructured":"Treister AD, Kraff-Cooper C, Lio PA. Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis. JAMA Dermatol. 2018;154(10):1208\u201311.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1367_CR29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0895-4356(96)00268-5","volume":"50","author":"JF Steiner","year":"1997","unstructured":"Steiner JF, Porchazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50(1):105\u201316.","journal-title":"J Clin Epidemiol"},{"issue":"10086","key":"1367_CR30","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, Simpson EL, Papp KA, Hong HC, Rubel D, Foley P, Prens E, Griffiths CEM, Etoh T, Pinto PH, Pujol RM, Szepietowski JC, Ettler K, Kem\u00e9ny L, Zhu X, Akinlade B, Hultsch T, Mastey V, Gadkari A, Eckert L, Amin N, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD, Shumel B. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287\u2013303. https:\/\/doi.org\/10.1016\/S0140-6736(17)31191-1.","journal-title":"Lancet"},{"issue":"8","key":"1367_CR31","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1001\/jamadermatol.2024.1536","volume":"160","author":"LA Beck","year":"2024","unstructured":"Beck LA, Bissonnette R, Deleuran M, et al. Dupilumab in adults with moderate to severe atopic dermatitis: a 5-year open-label extension study. JAMA Dermatol. 2024;160(8):805\u201312. https:\/\/doi.org\/10.1001\/jamadermatol.2024.1536.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"1367_CR32","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/jdv.17832","volume":"36","author":"ATM R\u00f8nnstad","year":"2022","unstructured":"R\u00f8nnstad ATM, Hansen PM, Halling AS, Egeberg A, Kolko M, Heegaard S, Thyssen JP. Factors associated with ocular surface disease and severity in adults with atopic dermatitis: a nationwide survey. J Eur Acad Dermatol Venereol. 2022;36(4):592\u2013601. https:\/\/doi.org\/10.1111\/jdv.17832.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1367_CR33","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jaip.2018.10.009","volume":"7","author":"K Govind","year":"2019","unstructured":"Govind K, Whang K, Khanna R, Scott AW, Kwatra SG. Atopic dermatitis is associated with increased prevalence of multiple ocular comorbidities. J Allergy Clin Immunol Pract. 2019;7(1):298\u20139. https:\/\/doi.org\/10.1016\/j.jaip.2018.10.009.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1367_CR34","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.1128","author":"RE Achten","year":"2022","unstructured":"Achten RE, Van Luijk C, Van der Rijst L, Bakker D, Spekhorst L, Zuithoff N, Schuttelaar M, Romeijn G, Voorberg A, Kamsteeg M, Haeck I, De Graaf M, Thijs J, De Boer J, De Bruin-Weller M. Identification of risk factors for dupilumab-associated ocular surface disease in patients with atopic dermatitis. Acta Derm Venereol. 2022. https:\/\/doi.org\/10.2340\/actadv.v102.1128.","journal-title":"Acta Derm Venereol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01367-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01367-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01367-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T16:15:43Z","timestamp":1743869743000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01367-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1367"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01367-5","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,13]]},"assertion":[{"value":"1 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jessica M. Franklin, Stephen Ezzy, Robert Gately, and Florence T. Wang are employees of Optum and may own stock in UnitedHealth Group. Andrea F. Marcus, Ihtisham Sultan, Ashley Howell, Jeannette Green, and Rachel E. Sobel are employees of and may own stock in Regeneron Pharmaceuticals, Inc. Rachel E. Sobel is a stockholder of Pfizer. Sarah J. Sinnott is an employee of and may own stock in Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Optum authors received approval to use the Optum Research Database for the purposes of this study. The study was also reviewed and approved by BRANY IRB; approval #21\u201310-294\u2013856.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}